Which nutrients does research link to cognitive changes in perimenopause?
B vitamins are the popular answer to this question, but the perimenopause-specific research points to different ingredients. Creatine HCl, citicoline, and pine bark each have published randomised controlled trials measuring cognitive performance outcomes in peri- or postmenopausal women. B vitamins have general cognitive research behind them, but very little that is specific to the perimenopause transition.
What the perimenopause-cognition question is actually asking
The question "which vitamins help with cognition in perimenopause?" is usually rooted in a practical observation: many women notice a change in how quickly they process information, how well they recall words mid-sentence, or how easily they sustain attention during cognitively demanding tasks. The popular answer — B vitamins — reflects general cognitive health advice that has spread far beyond its evidence base.
This article looks specifically at what has been studied in women during the perimenopause and menopause transition, not general population cognitive research. The distinction matters. A study in young male athletes, or in people with Alzheimer's disease, does not reliably transfer to a 47-year-old woman whose hormonal environment is changing.
There are currently three ingredients with peer-reviewed randomised controlled trials measuring cognitive or neurological outcomes specifically in perimenopausal or menopausal women: creatine HCl, pine bark, and citicoline (in the form of citicoline). Vitamin D3 has supporting evidence for neurological function but its perimenopause-specific cognitive data is less direct. B vitamins have a general evidence base for homocysteine management, but no perimenopause-specific cognitive RCTs of comparable quality.
Why B vitamins get so much attention — and what the evidence actually shows
B vitamins — particularly B6, B9 (folate) and B12 — are genuinely important for neurological function. They support the one-carbon metabolism pathway that regulates homocysteine levels, and elevated homocysteine is associated with increased risk of cognitive decline in older populations. This is real and established biochemistry.
The problem is that most of this research:
- Was conducted in older populations with confirmed deficiency, not healthy perimenopausal women
- Measured homocysteine levels as a proxy, not direct cognitive performance outcomes
- Did not isolate the perimenopause transition as a specific study context
The leap from "B vitamins support neurological biochemistry" to "B vitamins address cognitive changes specific to perimenopause" is not well supported in the primary literature. General nutritional sufficiency in B vitamins matters — but supplementation above sufficiency does not appear to produce additional cognitive benefit in women who are not deficient.
What the research shows on perimenopause-specific cognitive outcomes
Creatine HCl — reaction time and frontal brain creatine levels
Korovljev et al. (2026) conducted the CONCRET-MENOPA randomised controlled trial in 36 perimenopausal and menopausal women (mean age 50.1 years). Participants received creatine HCl at 1,500 mg per day, 750 mg per day, a combination supplement, or placebo for eight weeks. The primary measured cognitive outcome was reaction time, assessed using validated cognitive testing. At eight weeks, the 1,500 mg creatine HCl group showed a 6.6% improvement in reaction time compared with 1.2% in the placebo group (p<0.01). Frontal brain creatine levels, measured by magnetic resonance spectroscopy, increased by 16.4% in the treatment group versus 0.9% in placebo (p<0.01). All interventions were well tolerated. PubMed 40854087
The mechanism is specific to brain energy metabolism. Creatine phosphate is a substrate for adenosine triphosphate (ATP) resynthesis. The brain is one of the most energy-demanding organs in the body, and frontal lobe regions involved in attention, processing speed, and working memory rely heavily on creatine-phosphate buffering. This pathway is separate from hormonal regulation, which is why creatine's effect on brain bioenergetics does not depend on oestrogen status and may be relevant regardless of where a woman is in the perimenopause transition.
French maritime pine bark extract — measured cognitive outcomes and antioxidative markers
Yang, Liao, Zhu, Liao and Rohdewald (2007) ran a six-month randomised, double-blind, placebo-controlled trial in 155 perimenopausal women using 200 mg pine bark daily. Measured outcomes included the Women's Health Questionnaire (which includes cognitive subscales), antioxidative status, and lipid profile. All measured outcomes improved in the pine bark group, with antioxidative status significantly increased. PubMed 17653885
Ryan et al. (2008) studied 101 healthy elderly participants (aged 60–85) taking 150 mg pine bark daily for three months, measuring working memory and oxidative stress markers. Spatial working memory improved significantly in the pine bark group compared to the placebo group. Plasma F2-isoprostane levels — a measure of lipid peroxidation in nerve cell membranes — decreased significantly in the pine bark group but not in controls, pointing to antioxidant activity as a plausible cognitive mechanism. PubMed 18701642
pine bark's proposed cognitive mechanisms include its antioxidant activity (free radical scavenging), its anti-inflammatory properties, and its positive effect on endothelial function and cerebral blood flow — all of which are relevant to neurological performance rather than hormonal signalling.
Citicoline — frontal lobe bioenergetics and memory performance
Silveri, Dikan, Ross, Jensen, Kamiya, Kawada, Renshaw and Yurgelun-Todd (2008) studied 16 healthy adults (mean age 47.3 years) taking citicoline (CDP-choline) at 500 mg or 2,000 mg daily for six weeks. At the six-week mark, those taking 500 mg showed a 7% increase in phosphocreatine, a 14% increase in beta-nucleoside triphosphates (predominantly ATP), and a 32% increase in the phosphocreatine-to-inorganic-phosphate ratio in the anterior cingulate cortex — all statistically significant. Notably, the 500 mg dose produced greater effects than the 2,000 mg dose. PubMed 18816480
Nakazaki, Mah, Sanoshy, Citrolo and Watanabe (2021) conducted a 12-week randomised controlled trial in 100 healthy adults aged 50–85 with age-associated memory impairment. Those receiving citicolineat 500 mg daily showed significantly greater improvements in episodic memory (p=0.0025) and composite memory scores (p=0.0052) compared to placebo. PubMed 33978188
Citicoline works via a different pathway from creatine. As a precursor to phosphatidylcholine — a major structural component of neuronal cell membranes — citicoline supports membrane repair and synthesis. It also serves as a precursor to acetylcholine, the neurotransmitter most directly associated with attention and memory encoding. These are structural and neurotransmitter-level mechanisms, not energy-buffering mechanisms.
The honest picture on vitamin D3 and cognition
Vitamin D3 deserves a mention because its deficiency is widespread in the UK, and deficiency correlates with poorer cognitive outcomes in multiple population studies. However, it is important to distinguish between correcting a deficiency (well supported) and expecting supplementation to improve cognitive performance above sufficiency (less well established).
In the UK, vitamin D insufficiency is common — particularly during autumn and winter months, and particularly in women over 40 who may spend less time outdoors. The NHS recommends that all adults consider a daily vitamin D supplement of 400 IU during the winter months. Many researchers working in cognitive and neurological health use 1,000–2,000 IU daily as the dose range with a reasonable evidence base for addressing insufficiency without approaching upper safe limits. Correcting insufficiency is the primary goal; cognitive benefit is an associated outcome of getting baseline levels into a healthy range.
How these nutrients are used in The Foundation
The Foundation contains all three of the above ingredients at their research-matched doses. citicolineat 500 mg matches both the Silveri et al. (2008) bioenergetics trial and the Nakazaki et al. (2021) memory trial. pine bark at 200 mg matches the Yang et al. (2007) perimenopausal women trial — specifically the higher-dose arm. Saffron extract as saffron extract at 28 mg matches the Kell et al. (2017) dose-response trial. Vitamin D3 at 2,000 IU sits in the middle of the evidence-based range for addressing insufficiency.
Creatine HCl at 1,500 mg — matching the CONCRET-MENOPA medium-dose arm — is in Creatine Companion, available separately or together with The Foundation as The Krevie Routine.
The Foundation — citicoline500 mg · pine bark 200 mg · saffron extract 28 mg · Vitamin D3 2,000 IU · Vitamin K2 100 mcg. Every ingredient dosed to match its primary published clinical trial. View The Foundation.
Frequently asked questions
Do B vitamins help with cognitive performance in perimenopause?
B vitamins — particularly B6, B9, and B12 — support homocysteine metabolism and are important for baseline neurological health. However, the evidence for B vitamin supplementation specifically improving cognitive performance outcomes in perimenopausal women is limited. Most B vitamin cognitive research has been conducted in older populations with confirmed deficiency. General nutritional sufficiency matters; supplementation above sufficiency, in the absence of deficiency, has not shown consistent cognitive benefit in well-nourished women.
What nutrients have the strongest evidence for measured cognitive outcomes in perimenopause?
The ingredients with published randomised controlled trials measuring cognitive or neurological outcomes in peri- or postmenopausal women are creatine HCl (CONCRET-MENOPA, 2026), citicoline as citicoline (Silveri et al. 2008; Nakazaki et al. 2021), and pine bark (Yang et al. 2007). Each has a different mechanism: creatine supports brain energy metabolism, citicolinesupports membrane structure and neurotransmitter synthesis, and pine bark acts via antioxidant and endothelial pathways.
Why does mechanism matter — isn't the outcome all that counts?
Mechanism matters because it determines whether an ingredient's research is likely to transfer to your specific situation. Creatine's effect on brain ATP production does not depend on hormonal status, so it is relevant across the perimenopause timeline. An ingredient that works by influencing oestrogen levels requires a different evaluation — and carries different regulatory considerations under UK food supplement law.
Does citicolinework differently from regular choline supplements?
Yes. Choline is a simpler precursor compound. Citicoline (CDP-choline) is a more complex molecule that the body uses to synthesise both phosphatidylcholine (a key cell membrane component) and acetylcholine (a neurotransmitter). citicolineis a standardised, branded form of citicoline used in the majority of published cognitive research. Much of the evidence cited for "choline" in cognitive health was actually produced using citicolinespecifically — the two are not interchangeable in terms of the research base.
How long does it take for these nutrients to show a measured effect?
In the CONCRET-MENOPA trial, reaction time improvements were measured at eight weeks. In Silveri et al. (2008), frontal lobe bioenergetics changes were detected at six weeks of citicolinesupplementation. Nakazaki et al. (2021) measured memory outcomes at 12 weeks. pine bark's antioxidative effects were statistically significant at four weeks in some trials. None of these effects are expected to be detectable in one or two weeks, which is why clinical trial durations are designed specifically for eight to twelve weeks as the standard assessment window.
Further reading
- Creatine for women's brain health: what the evidence shows
- What happens to your body during perimenopause: a system-by-system guide
- Best supplements for perimenopause in the UK: a science-first guide
References
- Korovljev D, Ostojic J, Panic J, et al. The Effects of 8-Week Creatine Hydrochloride and Creatine Ethyl Ester Supplementation on Cognition, Clinical Outcomes, and Brain Creatine Levels in Perimenopausal and Menopausal Women (CONCRET-MENOPA): A Randomized Controlled Trial. 2026. PubMed 40854087
- Silveri MM, Dikan J, Ross AJ, Jensen JE, Kamiya T, Kawada Y, Renshaw PF, Yurgelun-Todd DA. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR Biomed. 2008;21(10):1066–75. PubMed 18816480
- Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F. Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Nutr. 2021;151(8):2153–2160. PubMed 33978188
- Yang HM, Liao MF, Zhu SY, Liao MN, Rohdewald P. A randomised, double-blind, placebo-controlled trial on the effect of pine bark on the climacteric syndrome in peri-menopausal women. Acta Obstet Gynecol Scand. 2007;86(8):978–85. PubMed 17653885
- Ryan J, Croft K, Mori T, et al. An examination of the effects of the antioxidant pine bark on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population. J Psychopharmacol. 2008;22(5):553–62. PubMed 18701642
Food supplements are not a substitute for a varied, balanced diet and a healthy lifestyle. Do not exceed the recommended daily dose. Always speak to your GP if you are taking medication or have a medical condition.
Leave a comment
This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.